SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway.

COVID-19 Nuclear factor erythroid 2-related factor 2 Oxidative stress SARS-CoV-2

Journal

Cell stress & chaperones
ISSN: 1466-1268
Titre abrégé: Cell Stress Chaperones
Pays: Netherlands
ID NLM: 9610925

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 24 04 2023
revised: 19 08 2023
accepted: 04 09 2023
medline: 16 1 2024
pubmed: 16 1 2024
entrez: 15 1 2024
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is a recent pandemic caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) leading to pulmonary and extra-pulmonary manifestations due to the development of oxidative stress (OS) and hyperinflammation. The underlying cause for OS and hyperinflammation in COVID-19 may be related to the inhibition of nuclear factor erythroid 2-related factor 2 (Nrf2), a master regulator of antioxidative responses and cellular homeostasis. The Nrf2 pathway inhibits the expression of pro-inflammatory cytokines and the development of cytokine storm and OS in COVID-19. Nrf2 activators can attenuate endothelial dysfunction (ED), renin-angiotensin system (RAS) dysregulation, immune thrombosis, and coagulopathy. Hence, this review aimed to reveal the potential role of the Nrf2 pathway and its activators in the management of COVID-19. As well, we tried to revise the mechanistic role of the Nrf2 pathway in COVID-19.

Identifiants

DOI: 10.1007/s12192-023-01379-0 PMID: 38225010
pubmed: 38225010
pii: S1355-8145(24)00021-X
doi: 10.1007/s12192-023-01379-0
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

657-673

Informations de copyright

© 2023 THE AUTHOR(S). Published by Elsevier Inc on behalf of Cell Stress Society International.

Auteurs

Rabab S Hamad (RS)

Biological Sciences Department, College of Science, King Faisal University, 31982, Al Ahsa, Saudi Arabia; Central Laboratory, Theodor Bilharz Research Institute, 12411, Giza, Egypt.

Hayder M Al-Kuraishy (HM)

Department of Pharmacology, Toxicology and Medicine, Medical Faculty, College of Medicine, Al-Mustansiriyah University, P.O. Box 14132, Baghdad, Iraq.

Athanasios Alexiou (A)

Department of Science and Engineering, Novel Global Community Educational Foundation, 2770, Hebersham, NSW, Australia; AFNP Med, 1030, Vienna, Austria.

Marios Papadakis (M)

Department of Surgery II, University Hospital Witten-Herdecke, University of Witten-Herdecke, Heusnerstrasse 40, 42283, Wuppertal, Germany. Electronic address: marios_papadakis@yahoo.gr.

Eman A Ahmed (EA)

Department of Pharmacology, Faculty of Veterinary Medicine, Suez Canal University, 41522, Ismailia, Egypt.

Hebatallah M Saad (HM)

Department of Pathology, Faculty of Veterinary Medicine, Matrouh University, 51744, Marsa Matruh, Egypt. Electronic address: heba.magdy@mau.edu.eg.

Gaber El-Saber Batiha (GE)

Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, 22511, Damanhour, Egypt. Electronic address: gaberbatiha@gmail.com.

Classifications MeSH